Advertisement

World Journal of Pediatrics

, Volume 15, Issue 6, pp 536–545 | Cite as

Childhood Langerhans cell histiocytosis: a disease with many faces

  • Alexander K. C. LeungEmail author
  • Joseph M. Lam
  • Kin Fon Leong
Review Article

Abstract

Background

Langerhans cell histiocytosis (LCH) is a group of diseases characterized by the proliferation and accumulation of Langerhans cells. Clinical presentations of LCH vary widely.

Data sources

A PubMed search was conducted using Clinical Queries with the key term “Langerhans cell histiocytosis”. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. This paper is based on, but not limited to, the search results.

Results

Generally, patients with LCH can be divided into two groups based on the extent of involvement at diagnosis, namely, single-system LCH and multisystem LCH. The involvement may be unifocal or multifocal. Patients with isolated bone lesions typically present between 5 and 15 years of age, whereas those with multisystem LCH tend to present before 5 years of age. The clinical spectrum is broad, ranging from an asymptomatic isolated skin or bone lesion to a life-threatening multisystem condition. Clinical manifestations include, among others, "punched out" lytic bone lesion, seborrheic dermatitis-like eruption, erythematous/reddish-brown crusted/scaly papules/maculopapules/plaques/patches, and eczematous lesions, diabetes insipidus, hepatosplenomegaly, cytopenias, lymphadenopathy, and an acute fulminant disseminated multisystem condition presenting with fever, skin rash, anemia, thrombocytopenia, lymphadenopathy, and hepatosplenomegaly. The diagnosis is clinicopathologic, based on typical clinical findings and histologic/immunohistochemical examination of a biopsy of lesional tissue. Positive CD1a, S100, and/or CD207 (Langerin) immunohistochemical staining of lesional cells is required for a definitive diagnosis. Watchful waiting is recommended for patients with skin-only LCH. Patients with symptomatic or refractory skin-only LCH may be treated with topical tacrolimus/corticosteroids, topical nitrogen mustard, oral methotrexate, or oral hydroxyurea. The current recommended first-line therapy for patients with multisystem LCH is 12 months therapy with prednisone and vinblastine. Mercaptopurine is added for patients with risk organ involvements.

Conclusions

Because of the broad spectrum of clinical manifestations and the extreme diversity of disease, LCH remains a diagnostic dilemma. Morphological identification of LCH cells and positive immunochemical staining with CD1a, S100, and/or CD207 (Langerin) of lesional cells are necessary for a definitive diagnosis.

Keywords

Cytopenia Diabetes insipidus Eczematous lesions Hepatosplenomegaly Lymphadenopathy Seborrheic dermatitis-like eruption 

Notes

Author contributions

AKCL wrote the first draft of the manuscript, as well as a statement of whether an honorarium, grant, or other form of payment was given to anyone to produce the manuscript. JML and KFL contributed to drafting and revising the manuscript. All authors have seen and approved the final version submitted for publication and take full responsibility for the manuscript.

Funding

There is no honorarium, grant, or other form of payment given to any of the authors/coauthors.

Compliance with ethical standards

Ethical approval

Not applicable.

Conflict of interest

No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.

References

  1. 1.
    Papadopoulou M, Panagopoulou P, Papadopoulou A, Hatzipantelis E, Efstratiou I, Galli-Tsinopoulou A, et al. The multiple faces of Langerhans cell histiocytosis in childhood: a gentle reminder. Mol Clin Oncol. 2018;8:489–92.PubMedGoogle Scholar
  2. 2.
    Yurkovich M, Wong A, Lam JM. Solitary congenital self-healing Langerhans cell histiocytosis: a benign variant of Langerhans cell histiocytosis? Dermatol Online J. 2013;19:3.PubMedGoogle Scholar
  3. 3.
    Papo M, Cohen-Aubart F, Trefond L, Bauvois A, Amoura Z, Emile JF, et al. Systemic histiocytosis (Langerhans cell histiocytosis, Erdheim–Chester disease, Destombes–Rosai–Dorfman disease): from oncogenic mutations to inflammatory disorders. Curr Oncol Rep. 2019;21:62.PubMedGoogle Scholar
  4. 4.
    Langerhans P. Uber die nerven der menschlichen haut. Arch Pathol Anat. 1868;44:325–7.Google Scholar
  5. 5.
    Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379:856–68.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Khung S, Budzik JF, Amzallag-Bellenger E, Lambilliote A, Soto Ares G, Cotten A, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013;4:569–79.PubMedPubMedCentralGoogle Scholar
  7. 7.
    McClain KL. Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis. In: Post TW, editor. Up To Date. Waltham, MA.Google Scholar
  8. 8.
    Flores-Terry MA, Sanz-Trenado JL, García-Arpa M, Cortina-de la Calle MP. Cutaneous Langerhans cell histiocytosis presenting in adulthood. Actas Dermosifiliogr. 2019;110:167–9.PubMedGoogle Scholar
  9. 9.
    Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M. Langerhans cell histiocytosis in children—a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatol Alergol. 2018;35:6–17.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Morren MA, Vanden Broecke K, Vangeebergen L, Sillevis-Smitt JH, Van Den Berghe P, Hauben E, et al. Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer. 2016;63:486–92.PubMedGoogle Scholar
  11. 11.
    Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019;178:771–6.PubMedGoogle Scholar
  12. 12.
    Bi L, Sun B, Lu Z, Shi Z, Wang D, Zhu Z. Langerhans cell histiocytosis with multisystem involvement in an infant: a case report. Exp Ther Med. 2015;9:2137–40.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Merglová V, Hrušák D, Boudová L, Mukenšnabl P, Valentová E, Hostička L. Langerhans cell histiocytosis in childhood—review, symptoms in the oral cavity, differential diagnosis and report of two cases. J Craniomaxillofac Surg. 2014;42:93–100.PubMedGoogle Scholar
  14. 14.
    Yoon JH, Park HJ, Park SY, Park BK. Langerhans cell histiocytosis in non-twin siblings. Pediatr Int. 2013;55:e73–e7676.PubMedGoogle Scholar
  15. 15.
    McCullough WP, Pollock AN. Langerhans cell histiocytosis presenting as chronic otitis externa. Pediatr Emerg Care. 2017;33:67–9.PubMedGoogle Scholar
  16. 16.
    Iraji F, Poostiyan N, Dehnavi PR, Soghrati M. Langerhans cell histiocytosis: a case report with unusual cutaneous manifestation. Adv Biomed Res. 2018;7:102.PubMedPubMedCentralGoogle Scholar
  17. 17.
    DiCaprio MR, Roberts TT. Diagnosis and management of Langerhans cell histiocytosis. J Am Acad Orthop Surg. 2014;22:643–52.PubMedGoogle Scholar
  18. 18.
    Peckham-Gregory EC, McClain KL, Allen CE, Scheurer ME, Lupo PJ. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018;28:521–8.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Aboud MJ, Kadhim MM. Langerhans-cell histiocytosis (LCH) a presentation of two siblings with two different entities. Springerplus. 2015;4:351.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Aricò M, Nichols K, Whitlock JA, Arceci R, Haupt R, Mittler U, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol. 1999;107:883–8.PubMedGoogle Scholar
  21. 21.
    Badalian-Very G, Vergilio JA, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156:163–72.PubMedGoogle Scholar
  22. 22.
    Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999;94:4195–201.PubMedGoogle Scholar
  23. 23.
    Crooks B, Grenier D. Langerhans cell histiocytosis: a complex recurrent disease. Paediatr Child Health. 2010;15:69–70.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56:451–61.PubMedGoogle Scholar
  25. 25.
    Tillotson CV, Patel BC. Langerhans cell histiocytosis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019.Google Scholar
  26. 26.
    Monsereenusorn C, Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin N Am. 2015;29:853–73.Google Scholar
  27. 27.
    Nann D, Schneckenburger P, Steinhilber J, Metzler G, Beschorner R, Schwarze CP, et al. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae. Ann Hematol. 2019;98:1617–1626.PubMedGoogle Scholar
  28. 28.
    Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis. Pediatr Dev Pathol. 2019;9:1093526619847859.  https://doi.org/10.1177/1093526619847859.CrossRefGoogle Scholar
  29. 29.
    Thacker NH, Abla O. Pediatric Langerhans cell histiocytosis: state of the science and future directions. Clin Adv Hematol Oncol. 2019;17:122–31.PubMedGoogle Scholar
  30. 30.
    Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol. 2018;78:1035–44.PubMedGoogle Scholar
  31. 31.
    Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008;20:23–9.PubMedGoogle Scholar
  32. 32.
    Bender NR, Seline AE, Siegel DH, Sokumbi O. Langerhans cell histiocytosis with prominent nail involvement. J Cutan Pathol. 2019;46:1–5.PubMedGoogle Scholar
  33. 33.
    Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008;25:291–5.PubMedGoogle Scholar
  34. 34.
    Donadieu J, Chalard F, Jeziorski E. Medical management of Langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13:1309–22.PubMedGoogle Scholar
  35. 35.
    Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60:175–84.PubMedGoogle Scholar
  36. 36.
    Jeunon T, Sousa MA, Santos-Rodrigues N, Lopes R. Langerhans cell histiocytosis—a case report. Dermatol Pract Concept. 2012;2:25–9.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Windebank K, Nanduri V. Langerhans cell histiocytosis. Arch Dis Child. 2009;94:904–8.PubMedGoogle Scholar
  38. 38.
    Grifo AH. Langerhans cell histiocytosis in children. J Pediatr Oncol Nurs. 2009;26:41–7.PubMedGoogle Scholar
  39. 39.
    Hu S, Wang W, Wang C, Ma R, Xiao Z, Dong H. Langerhans cell histiocytosis presenting as a multi-system disorder in an infant. Int J Dermatol. 2012;51:709–12.PubMedGoogle Scholar
  40. 40.
    Mehta B, Amladi S. Langerhans cell histiocytosis presenting as hypopigmented papules. Pediatr Dermatol. 2010;27:215–7.PubMedGoogle Scholar
  41. 41.
    Chan MMH, Tan DJA, Koh MJ, Tan LS. Blistering Langerhans cell histiocytosis. Lancet Oncol. 2018;19:e500.PubMedGoogle Scholar
  42. 42.
    Fernández Armenteros JM, Arco Huguet N, Sanmartin Novell V, Vilardell Villellas F, Velasco Sanchez A, Martró Català E, et al. Langerhans cell histiocytosis mimicking molluscum contagiosum: a case series. Pediatr Blood Cancer. 2018;65:e27047.PubMedGoogle Scholar
  43. 43.
    Karpman MS, AlJasser MI, Lam JM. Molluscum contagiosum-like presentation of Langerhans cell histiocytosis: a case and review. Pediatr Dermatol. 2017;34:e288–e9.PubMedGoogle Scholar
  44. 44.
    Mori S, Adar T, Kazlouskaya V, Alexander JB, Heilman E, Glick SA. Cutaneous Langerhans cell histiocytosis presenting with hypopigmented lesions: report of two cases and review of literature. Pediatr Dermatol. 2018;35:502–6.PubMedGoogle Scholar
  45. 45.
    PDQ Pediatric Treatment Editorial Board. Langerhans cell histiocytosis treatment (PDQ®): Health professional version. PDQ cancer information summaries [Internet]. Bethesda: National Cancer Institute (US). 2002–2019.Google Scholar
  46. 46.
    Wollina U, Langner D, Hansel G, Schönlebe J. Cutaneous Langerhans cell histiocytosis: the spectrum of a rare cutaneous neoplasia. Wien Med Wochenschr. 2018;168:243–7.PubMedGoogle Scholar
  47. 47.
    Figueras-Nart I, Vicente A, Sánchez-Schmidt J, Jou-Muñoz C, Bordas-Orpinell X, Celis-Passini VP, et al. Langerhans cell histiocytosis presenting as fingernail changes. JAAD Case Rep. 2016;2:485–7.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Sabui TK, Purkait R. Nail changes in Langerhans cell histiocytosis. Indian Pediatr. 2009;46:728–9.PubMedGoogle Scholar
  49. 49.
    Aviner S, Ronen M, London D, Tobar A, Zangen S. Langerhans cell histiocytosis in a premature baby presenting with skin-isolated disease: case report and literature review. Acta Paediatr. 2008;97:1751–4.PubMedGoogle Scholar
  50. 50.
    Murata S, Yoshida Y, Adachi K, Morita E, Yamamoto O. Solitary, late-onset, self-healing Langerhans cell histiocytosis. Acta Derm Venereol. 2011;91:103–4.PubMedGoogle Scholar
  51. 51.
    Pettinger KJ, Solman L, Mathew B, Taylor G, Clark S, Picton S. Cutaneous Langerhans cell histiocytosis presenting in a neonate. Arch Dis Child. 2018;103:993.PubMedGoogle Scholar
  52. 52.
    Yu J, Rubin AI, Castelo-Soccio L, Perman MJ. Congenital self-healing Langerhans cell histiocytosis. J Pediatr. 2017;184:232–232.e1.PubMedGoogle Scholar
  53. 53.
    Kim JE, Kim BJ, Kang H. Solitary congenital erosion in a newborn: report of a solitary congenital self-healing reticulohistiocytosis. Ann Dermatol. 2014;26:250–3.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Mandel VD, Ferrari C, Cesinaro AM, Pellacani G, Del Forno C. Congenital, “self-healing” Langerhans cell histiocytosis (Hashimoto–Pritzker disease): a report of two cases with the same cutaneous manifestations but different clinical course. J Dermatol. 2014;41:1098–101.PubMedGoogle Scholar
  55. 55.
    Parimi LR, You J, Hong L, Zhang F. Congenital self-healing reticulohistiocytosis with spontaneous regression. An Bras Dermatol. 2017;92:553–5.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Dabas A, Batra A, Khadgawat R, Jyotsna VP, Bakhshi S. Growth and endocrinal abnormalities in pediatric Langerhans cell histiocytosis. Indian J Pediatr. 2016;83:657–60.PubMedGoogle Scholar
  57. 57.
    Garofalo D, Cutfield R. Pituitary involvement in Langerhans-cell histiocytosis. N Z Med J. 2010;123:88–91.PubMedGoogle Scholar
  58. 58.
    Leung AK, McArthur RG. Histiocytosis X: sequential involvement of thirst and antidiuretic hormone centres. J R Soc Med. 1988;81:109–10.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Bravo MT, Garmendia M, Blanco SB, Etxezarraga C, Paja M. Langerhans cell histiocytosis: a rare cause of cholestasis in adult patients. Case report. Rev Esp Enferm Dig. 2010;102:571–2.PubMedGoogle Scholar
  60. 60.
    Leung AK, Chan KW. Iron deficiency anemia. Adv Pediatr. 2001;48:385–408.PubMedGoogle Scholar
  61. 61.
    McClain KL. Treatment of Langerhans cell histiocytosis. In: Post TW, editor. Up To Date. Waltham, MA. Accessed 22 June 2019.Google Scholar
  62. 62.
    Frade AP, Godinho MM, Batalha ABW, Bueno APS. Congenital Langerhans cell histiocytosis: a good prognosis disease? An Bras Dermatol. 2017;92:40–2.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Maglie R, Vannucchi M, Quintarelli L, Caproni M, Massi D, Antiga E. At the root: cutaneous Langerhans cell histiocytosis. Am J Med. 2018;131:922–6.PubMedGoogle Scholar
  64. 64.
    Park L, Schiltz C, Korman N. Langerhans cell histiocytosis. J Cutan Med Surg. 2012;1:45–9.Google Scholar
  65. 65.
    Yang YS, Byun YS, Kim JH, Kim HO, Park CW. Infantile scabies masquerading as Langerhans cell histiocytosis. Ann Dermatol. 2015;27:349–51.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Behera B, Malathi M, Prabhakaran N, Divya K, Thappa DM, Srinivas BH. Dermoscopy of Langerhans cell histiocytosis. J Am Acad Dermatol. 2017;76:S79–S81.PubMedGoogle Scholar
  67. 67.
    Ece D, Sahiner N, Ozkaya-Parlakay A, Oguz-Erdogan AS, Ozyoruk D, Tezer H, et al. Langerhans cell histiocytosis presenting like lichen planus in a 4-month-old infant. Pediatr Neonatol. 2018;59:219–20.PubMedGoogle Scholar
  68. 68.
    Lozano Masdemont B, Gómez-Recuero Muñoz L, Villanueva Álvarez-Santullano A, Parra Blanco V, Campos Domínguez M. Langerhans cell histiocytosis mimicking lichen nitidus with bone involvement. Australas J Dermatol. 2017;58:231–3.PubMedGoogle Scholar
  69. 69.
    Leung AK. The natural history of molluscum contagiosum in children. Lancet Infect Dis. 2015;15:136–7.Google Scholar
  70. 70.
    Leung AKC, Barankin B, Hon KLE. Molluscum contagiosum: an update. Recent Pat Inflamm Allergy Drug Discov. 2017;11:22–31.Google Scholar
  71. 71.
    Kalpana S, Lakshmi V. Systemic congenital Langerhans cell histiocytosis masquerading as diffuse neonatal hemangiomatosis. Indian Pediatr. 2018;55:613.PubMedGoogle Scholar
  72. 72.
    Leung AK, Rafaat M. Benign neonatal hemangiomatosis. Pediatr Dermatol. 2003;20:161–3.PubMedGoogle Scholar
  73. 73.
    Rubio-González B, García-Bracamonte B, Ortiz-Romero PL, Postigo-Llorente C, Vanaclocha-Sebastián F. Multisystemic Langerhans cell histiocytosis mimicking diffuse neonatal hemangiomatosis. Pediatr Dermatol. 2014;31:e87–9.PubMedGoogle Scholar
  74. 74.
    Leung AKC, Lam JM, Leong KF. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation, and management. Curr Pediatr Rev. 2019;15:42–6.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Billings TL, Barr R, Dyson S. Langerhans cell histiocytosis mimicking malignant melanoma: a diagnostic pitfall. Am J Dermatopathol. 2008;30:497–9.PubMedGoogle Scholar
  76. 76.
    Punja M, McWey RP, Heller M. Lytic lesion. J Emerg Med. 2013;44:179–80.PubMedGoogle Scholar
  77. 77.
    Leung AKC, Robson WLM, Halperin ML. Polyuria in childhood. Clin Pediatr. 1991;30:634–40.Google Scholar
  78. 78.
    Leung AK, Rafaat M. Eruption associated with amoxicillin in a patient with infectious mononucleosis. Int J Dermatol. 2003;42:553–5.PubMedGoogle Scholar
  79. 79.
    Leung AKC, Leong KF, Lam JM. A case of congenital syphilis presenting with unusual skin eruptions. Case Rep Pediatr. 2018;2018:1761454.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Ramachandran R. Case 3: hepatosplenomegaly in a 2-year-old boy. Pediatr Rev. 2015;36:265–7.PubMedGoogle Scholar
  81. 81.
    Berliner N. Approach to the adult with unexplained pancytopenia. In: Post TW, editor. UpToDate. Waltham, MA. Accessed 12 June 2019.Google Scholar
  82. 82.
    Sharma R, Nalepa G. Evaluation and management of chronic pancytopenia. Pediatr Rev. 2016;37:101–11 (quiz 112-3).PubMedPubMedCentralGoogle Scholar
  83. 83.
    Leung AK, Hon KL, Leong KF, Sergi CM. Measles: a disease often forgotten but not gone. Hong Kong Med J. 2018;24:512–20.Google Scholar
  84. 84.
    Leung AKC, Hon KL, Leong KF. Rubella (German measles) revisited. Hong Kong Med J. 2019;25:134–41.PubMedGoogle Scholar
  85. 85.
    Leung AK, Robson WL. Childhood cervical lymphadenopathy. J Pediatr Health Care. 2004;18:3–7.PubMedGoogle Scholar
  86. 86.
    Leung AK, Davies HD. Cervical lymphadenitis: etiology, diagnosis, and management. Curr Infect Dis Rep. 2009;11:183–9.PubMedGoogle Scholar
  87. 87.
    Herman TE, Siegel MJ. Langerhans cell histiocytosis: radiographic images in pediatrics. Clin Pediatr (Phila). 2009;48:228–31.PubMedGoogle Scholar
  88. 88.
    Madasu A, Noor Rana A, Banat S, Humad H, Mustafa R, AlJassmi AM. Langerhans cell histiocytosis in an infant mimicking a lymphoma at presentation. Case Rep Hematol. 2015;2015:670843.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Leung AKC, Leong KF, Lam JM. Onychomadesis in a 20-month-old child with Kawasaki disease. Case Rep Pediatr. 2019;2019:3156736.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173:663–70.PubMedGoogle Scholar
  91. 91.
    Leung AKC, Leung AAC. Evaluation and management of the child with hypothyroidism. World J Pediatr. 2019;15:124–34.PubMedGoogle Scholar
  92. 92.
    Ma J, Laird JH, Chau KW, Chelius MR, Lok BH, Yahalom J. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med. 2019;8:58–66.PubMedGoogle Scholar
  93. 93.
    Park IS, Park IK, Kim EK, Kim S, Jeon SR, Huh JR, et al. Langerhans cell histiocytosis followed by Hodgkin's lymphoma. Korean J Intern Med. 2012;27:459–62.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19:233–42.PubMedGoogle Scholar
  95. 95.
    Chow TW, Leung WK, Cheng FWT, Kumta SM, Chu WCW, Lee V, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102:830–5.PubMedGoogle Scholar
  96. 96.
    Kaiserian M, Altberg G, Greenstein J, Hahn B. Langerhans cell histiocytosis. J Emerg Med. 2019;56:e31–2.PubMedGoogle Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine 2019

Authors and Affiliations

  1. 1.Department of PediatricsThe University of Calgary, and The Alberta Children’s HospitalCalgaryCanada
  2. 2.Department of PediatricsUniversity of British ColumbiaVancouverCanada
  3. 3.Department of Dermatology and Skin SciencesUniversity of British ColumbiaVancouverCanada
  4. 4.Pediatric InstituteKuala Lumpur General HospitalKuala LumpurMalaysia

Personalised recommendations